NCT01009944

Brief Summary

The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2007

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

November 6, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 9, 2009

Completed
9.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 19, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 19, 2019

Completed
Last Updated

April 9, 2021

Status Verified

April 1, 2021

Enrollment Period

12.2 years

First QC Date

November 6, 2009

Last Update Submit

April 7, 2021

Conditions

Hypertension

Keywords

High blood pressure

Outcome Measures

Primary Outcomes (1)

  • One type of blood pressure medication will better treat individuals with certain genetic backgrounds.

    16 weeks

Study Arms (1)

Lisinopril, Atenolol

EXPERIMENTAL
Drug: Lisinopril, Atenolol

Interventions

Lisinopril, AtenololDRUG

once a day for 14 weeks

Also known as: Tenormin (Atenolol), Prinivil, Zestril (Lisinopril)
Lisinopril, Atenolol

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female hypertensive participants who were previously studied in SCOR program.

You may not qualify if:

  • Diabetes
  • Taking other medications beside thyroid or estrogen supplements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Hypertension

Interventions

LisinoprilAtenolol

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

DipeptidesOligopeptidesPeptidesAmino Acids, Peptides, and ProteinsPhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAmines

Study Officials

  • Gordon H. Williams, MD

    Brigham and Women's Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief, Cardiovascular Endocrinology Section

Study Record Dates

First Submitted

November 6, 2009

First Posted

November 9, 2009

Study Start

January 1, 2007

Primary Completion

March 19, 2019

Study Completion

March 19, 2019

Last Updated

April 9, 2021

Record last verified: 2021-04

Locations

US(1)